Can I Take Ashwagandha with Vardenafil (Levitra/Staxyn)?

What Is Vardenafil and How Does It Work?

Vardenafil is a phosphodiesterase type-5 (PDE5) inhibitor approved by the FDA for erectile dysfunction. It blocks the PDE5 enzyme in penile smooth muscle, allowing cyclic GMP to accumulate, smooth muscle to relax, and blood flow to increase in response to sexual stimulation. The FDA-approved dose range is 5 to 20 mg taken 60 minutes before sexual activity, with a maximum frequency of once daily [1].

Vardenafil Pharmacokinetics

Vardenafil reaches peak plasma concentration (Tmax) in roughly 0.7 to 0.9 hours after oral dosing and has a half-life of 4 to 5 hours, meaning clinically significant plasma levels persist for 4 to 6 hours [1]. The drug is metabolized primarily by hepatic CYP3A4, with minor contributions from CYP3A5 and CYP2C9 [2]. Any agent that inhibits or induces CYP3A4 can shift vardenafil exposure meaningfully upward or downward.

Known Drug Interactions Already on the Label

The prescribing information flags strong CYP3A4 inhibitors (ketoconazole, ritonavir), nitrates, and alpha-blockers as the most consequential interactions [1]. Combining vardenafil with nitrates is contraindicated because of the risk of severe hypotension. That mechanistic template matters here: anything that lowers blood pressure additively deserves the same scrutiny, even if it comes from a supplement aisle rather than a pharmacy.

What Is Ashwagandha and What Does It Do Physiologically?

Ashwagandha (Withania somnifera) is an adaptogenic herb whose active constituents include withanolides, alkaloids, and saponins. Systematic review evidence supports modest effects on cortisol, thyroid hormones, testosterone, and vascular function [3].

Blood Pressure and Nitric Oxide Effects

A randomized, double-blind trial by Choudhary et al. (2017, N=64) found that 300 mg ashwagandha root extract twice daily for 8 weeks produced a statistically significant reduction in serum cortisol (mean reduction 27.9%, P<0.05) and self-reported stress scores compared with placebo [4]. Cortisol reduction is clinically relevant here because elevated cortisol suppresses endothelial nitric oxide synthase (eNOS) activity; reducing cortisol may therefore increase baseline NO bioavailability.

A 2021 trial by Tiwari et al. (N=50) measuring cardiovascular parameters found small but significant reductions in resting systolic blood pressure (mean reduction approximately 5 mmHg) after 12 weeks of ashwagandha supplementation [5]. That is a modest effect on its own. Combined with the 5 to 10 mmHg systolic reduction typical with vardenafil, the aggregate drop could approach 10 to 15 mmHg in some individuals [1].

Testosterone and the HPG Axis

A 16-week RCT in overweight men (N=57) published in 2019 found that KSM-66 ashwagandha 600 mg daily raised serum testosterone by a mean of 14.7% compared with placebo (P<0.05) [6]. A meta-analysis of five RCTs (N=284 total participants) published in Andrology confirmed a statistically significant pooled increase in testosterone with ashwagandha supplementation [7]. Elevated testosterone does not directly amplify PDE5-inhibitor activity, but testosterone is required for normal NO-mediated erectile function, and testosterone deficiency blunts PDE5-inhibitor response [8]. So the testosterone-supporting effect of ashwagandha is not antagonistic to vardenafil; it may be directionally complementary.

Thyroid Hormone Effects

A randomized controlled trial by Sharma et al. (2018, N=50) showed that ashwagandha root extract 600 mg daily for 8 weeks significantly increased serum T3 (by 41.5%) and T4 (by 19.6%) in healthy adults compared with placebo [9]. Both hypothyroidism and hyperthyroidism alter cardiovascular hemodynamics. Hypothyroidism reduces cardiac output and may blunt vasodilatory responses; hyperthyroidism raises resting heart rate and can amplify hypotensive episodes. A patient moving from subclinical hypothyroid to euthyroid status on ashwagandha could experience a shift in their baseline hemodynamic profile right as vardenafil is taken.

The Core Pharmacodynamic Interaction: Additive Hypotension

This is the most clinically plausible concern. Both vardenafil and ashwagandha lower blood pressure through independent pathways.

Vardenafil's Hemodynamic Footprint

The vardenafil prescribing information reports mean maximum decreases in supine systolic BP of approximately 7 mmHg and diastolic BP of approximately 8 mmHg at 20 mg in healthy volunteers [1]. These decreases are generally well tolerated in healthy men but can become symptomatic (dizziness, presyncope) in individuals who are volume-depleted, on antihypertensives, or who have baseline hypotension.

Ashwagandha's Hemodynamic Footprint

The approximately 5 mmHg systolic reduction observed in the Tiwari et al. Trial [5] is additive in a simple arithmetic model. A man with a resting BP of 118/76 mmHg taking both agents simultaneously could theoretically experience peak systolic values near 105 to 110 mmHg, which is within the symptomatic range for some individuals, particularly those who are standing or exercising.

Who Is at Greatest Risk

Men on concurrent antihypertensive medication carry the highest risk of symptomatic hypotension from this combination. The FDA label for vardenafil already warns about co-administration with antihypertensives and specifically flags alpha-blocker use [1]. Adding ashwagandha on top of an antihypertensive plus vardenafil represents a three-way additive interaction that warrants explicit clinical review.

The Pharmacokinetic Question: Does Ashwagandha Affect CYP3A4?

Vardenafil's primary clearance pathway is hepatic CYP3A4 [2]. If ashwagandha meaningfully inhibits CYP3A4, vardenafil plasma levels could rise, amplifying both desired and adverse effects.

In Vitro Evidence

Several withanolides have shown CYP3A4 inhibitory activity in cell-based assays. A study published in Drug Metabolism and Disposition identified withanolide A and withaferin A as moderate CYP3A4 inhibitors in human liver microsomes [10]. The clinical significance of in vitro CYP inhibition is notoriously difficult to extrapolate to in vivo conditions; many compounds inhibit CYP enzymes at concentrations far above those achieved with typical oral supplementation.

Clinical Pharmacokinetic Data

As of early 2025, no published human pharmacokinetic study has directly measured the effect of ashwagandha co-administration on vardenafil AUC or Cmax. That absence of data is not the same as evidence of no interaction. The Natural Medicines database rates this combination as having insufficient evidence for a definitive pharmacokinetic classification. Given the 4 to 5 hour half-life of vardenafil and the standard once-daily dosing of ashwagandha, any CYP-based interaction would be most relevant if ashwagandha is taken within 2 to 3 hours of a vardenafil dose.

A Practical Risk-Stratification Framework for Patients Already Taking Both

Because some patients are already combining these agents before speaking with a clinician, a structured approach is useful. The framework below is intended to guide the clinical conversation, not replace it.

Group 1: Low hemodynamic risk. No antihypertensives, normal resting BP (systolic 110 to 130 mmHg), no history of orthostatic hypotension. These patients may tolerate the combination without incident. Monitoring blood pressure at home before and 1 hour after a combined dose is reasonable.

Group 2: Moderate hemodynamic risk. On one antihypertensive agent, resting systolic BP 100 to 115 mmHg, or age above 65 years. A clinician should review the combination. Timing separation (taking ashwagandha in the morning and vardenafil in the evening, or vice versa) reduces but does not eliminate overlap given ashwagandha's multi-hour pharmacodynamic effects.

Group 3: High hemodynamic risk. On two or more antihypertensives, history of syncopal episodes, or confirmed cardiac disease. Avoid combining without explicit cardiologist or urologist sign-off. The FDA label for vardenafil already advises particular caution in patients with cardiovascular disease [1].

Cortisol Modulation and Its Downstream Relevance to Erectile Function

Chronic psychological stress and elevated cortisol are recognized contributors to erectile dysfunction. A review published in Sexual Medicine Reviews noted that cortisol excess suppresses gonadotropin-releasing hormone, reduces LH pulsatility, and directly inhibits Leydig cell testosterone synthesis [11]. Ashwagandha's cortisol-lowering effect could therefore address a root-cause contributor to ED that vardenafil does not touch, since vardenafil acts purely on the vascular effector pathway.

This means the two agents may address ED through different mechanisms and in a sense operate on non-overlapping physiological targets. That is directionally favorable for efficacy but does not reduce the hemodynamic interaction concern already described.

What the Guidelines Say About Supplements and PDE5 Inhibitors

The American Urological Association (AUA) 2018 guideline on erectile dysfunction does not endorse any herbal supplement as a first-line or adjunct treatment for ED [12]. The guideline states: "Clinicians should not recommend herbal or other alternative therapies to improve erectile function, as there is insufficient evidence to support their use." That language reflects the evidence gap at the time of publication; it does not specifically address safety of combining supplements with PDE5 inhibitors.

The Endocrine Society's 2018 guideline on testosterone therapy notes that testosterone status modifies PDE5-inhibitor response, and that men with biochemically confirmed hypogonadism who fail PDE5 inhibitors should have testosterone levels corrected before assuming treatment failure [8]. Ashwagandha's modest testosterone-raising effect sits in a gray zone: it is unlikely to normalize frank hypogonadism (total testosterone <300 ng/dL) but may support testosterone levels in men in the low-normal range.

Monitoring Parameters If You Continue Both

If a clinician has reviewed the combination and the patient continues both agents, the following monitoring approach is reasonable based on the pharmacology described above:

Blood Pressure Monitoring

Home BP readings taken in the morning (before ashwagandha) and again 1 hour after vardenafil provide a practical before-and-after picture. Symptomatic hypotension (dizziness on standing, lightheadedness during or after sexual activity) should prompt immediate dose review.

Thyroid Function

Patients with pre-existing thyroid conditions or those taking thyroid medication should have TSH, free T3, and free T4 measured at baseline and again after 8 to 12 weeks on ashwagandha. The 41.5% T3 increase observed in the Sharma et al. Trial [9] is large enough to push a borderline hypothyroid patient into a euthyroid or even mildly hyperthyroid state, changing their cardiovascular reactivity.

Testosterone and Sexual Function

A validated questionnaire such as the International Index of Erectile Function (IIEF-5) at baseline and at 12 weeks gives objective data on whether the combination is producing a net clinical benefit. Serum total testosterone should be checked if clinical hypogonadism is a concern.

Dose and Timing Considerations

Standard ashwagandha extract doses in clinical trials range from 300 mg once daily to 600 mg twice daily of a standardized root extract (typically 5% withanolides) [3]. Lower doses (300 mg/day) are associated with smaller magnitude cortisol and BP effects than 600 mg twice-daily regimens, so dose matters when estimating interaction magnitude.

Vardenafil's Tmax of roughly 0.7 to 0.9 hours and its 4 to 5 hour half-life mean peak plasma levels and the associated BP nadir occur within the first 2 hours after dosing [1]. Taking ashwagandha 6 or more hours before or after vardenafil minimizes temporal overlap, though the BP-lowering effects of ashwagandha (driven by cortisol reduction and NO mechanisms) are chronic rather than acute and cannot be fully separated by timing alone.

Special Populations

Men Over 65

Older men have higher rates of orthostatic hypotension at baseline and are more likely to be on antihypertensives. The vardenafil label recommends a starting dose of 5 mg in men over 65, reflecting age-related pharmacokinetic changes [1]. Adding ashwagandha in this group warrants extra caution.

Men with Diabetes

Diabetic autonomic neuropathy reduces baroreceptor sensitivity, making these patients more vulnerable to symptomatic hypotension when BP-lowering agents are combined. The ADA Standards of Care note that ED is prevalent in 35 to 75% of men with diabetes [13]. Many diabetic patients with ED are already on antihypertensives and are potential users of both supplements and PDE5 inhibitors, making this a real-world high-risk intersection.

Men on Thyroid Medication

Ashwagandha raises T3 and T4 [9]; patients already on levothyroxine or liothyronine may experience an overshoot into hyperthyroidism if they add ashwagandha without adjusting their thyroid dose. Hyperthyroid states increase heart rate and can amplify the BP-lowering effects of vardenafil more unpredictably.